Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Oisquercq – page 95

1 851 clinical trials in Oisquercq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Oisquercq at a glance
1 851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 851 trials in Oisquercq

Open in trial search

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BT-001
  • Sponsor:Transgene

Atrial fibrillation+1

Not recruiting

Study on Edoxaban for Patients with Atrial Fibrillation and Previous Brain Bleeding

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Edoxaban
  • Sponsor:Hamilton Health Sciences Corporation

Asthma

Not recruiting

Study on Omalizumab and Mepolizumab for Patients with Severe Allergic and Eosinophilic Asthma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mepolizumab
  • Sponsor:Cliniques Universitaires Saint-Luc

Cough

Not recruiting

Study on the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) for Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Taplucainium Chloride
  • Sponsor:Nocion Therapeutics Inc.

Study of TX000045 for Pulmonary Hypertension in Heart Failure Patients with Preserved Ejection Fraction

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TX000045
  • Sponsor:Tectonic Therapeutic Inc.

Asthma

Not recruiting

Study on the Safety and Effectiveness of AZD8630 for Adults with Uncontrolled Asthma at Risk of Exacerbations

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of Durvalumab, Tremelimumab, and Cisplatin for Patients with Resectable, Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:UZ Leuven

Study on the Safety and Effectiveness of Opelconazole with Other Antifungal Treatments for Patients with Hard-to-Treat Lung Aspergillosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Opelconazole
  • Sponsor:Pulmocide Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Oisquercq

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, evaluating innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Outbreak Prevention
  • Treatment Efficacy

The study aims to assess a new therapeutic intervention for reducing the frequency of herpes episodes through a controlled, double-blind methodology.

02 Viral Disease Control

Research examining the effectiveness of preventive treatments for patients who experience six or more herpes episodes annually.

  • Viral Suppression
  • Long-term Management
  • Quality of Life Impact

The trial evaluates treatment outcomes over a 12-month period, focusing on reducing infection recurrence rates.

03 Clinical Therapeutics

Investigation of placebo-controlled interventions designed to address recurring viral infections affecting the orofacial region.

  • Treatment Innovation
  • Symptom Control
  • Patient Response

This research emphasizes the development of effective strategies for managing frequent herpes outbreaks.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.